Antibody & Phage Display Shared Resource

Information

  • Research Project
  • 10270219
  • ApplicationId
    10270219
  • Core Project Number
    P30CA045508
  • Full Project Number
    2P30CA045508-34
  • Serial Number
    045508
  • FOA Number
    PAR-20-043
  • Sub Project Id
    5890
  • Project Start Date
    8/1/1997 - 27 years ago
  • Project End Date
    7/31/2026 - a year from now
  • Program Officer Name
  • Budget Start Date
    9/15/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    34
  • Suffix
  • Award Notice Date
    9/15/2021 - 3 years ago

Antibody & Phage Display Shared Resource

ANTIBODY & PHAGE DISPLAY SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The Antibody & Phage Display Shared Resource offers a variety of cutting-edge technologies to develop antibodies for use as key research reagents. The Shared Resource is led by Faculty Head Adrian Krainer, Ph.D, and Director Johannes Yeh, Ph.D. The Shared Resource collaborates with Cancer Center members to address fundamental and compelling questions in cancer biology, in research areas including: (1) The understanding of the tumor microenvironment; (2) The discovery of surface biomarkers and their differential expression during tumorigenesis; and (3) Receptor signaling in cancer. Shared Resource staff work closely with scientists to select the best approach for their experimental needs, and specialized screens are developed in close coodination with individual scientists. The Shared Resource also tests and implements new techniques, reagents, and assay improvements related to the different stages of antibody production. Technologies currently available in the Shared Resource include hybridoma development by fusion of rodent spleen cells with immortalized cell lines, generation of nanobodies from immunized alpacas, and direct cloning of the VH-VL domains from B cells from immunized rodents or alpacas into expression plasmids. Yeast or phage display techniques are used to optimize the binding affinities of antibodies identified after the first round of immunization and selection. A library of hybridomas generated in the Shared Resource is maintained, and staff will produce and purify antibodies from these lines on request. In the last funding period this Shared Resouce was used by twelve Cancer Center members (32%), and has contributed towards seven publications by members. Novel antibodies have generated reagents that have been used for genomics (e.g., ChIP), cell separation (e.g., FACS), and single-cell analysis. Finally, recently developed antibodies are currently being investigated for potential diagnostic or therapeutic applications by members, and are thus playing an essential role in cancer programs at CSHL.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    P30
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
    122707
  • Indirect Cost Amount
    112890
  • Total Cost
  • Sub Project Total Cost
    235597
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NCI:235597\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    NCI
  • Study Section Name
    Subcommittee I - Transistion to Independence
  • Organization Name
    COLD SPRING HARBOR LABORATORY
  • Organization Department
  • Organization DUNS
    065968786
  • Organization City
    COLD SPRING HARBOR
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    117242209
  • Organization District
    UNITED STATES